You need JavaScript to view this

Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer

Journal Article:

Abstract

Whole-body fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging was performed during the follow-up of 33 patients suffering from differentiated thyroid cancer. Among them there were 26 patients with papillary and seven with follicular tumours. Primary tumour stage (pT) was pT1 in six cases, pT2 in eight cases, pT3 in three cases and pT4 in 14 cases. FDG PET was normal in 18 patients. In three patients a slightly increased metabolism was observed in the thyroid bed, assumed to be related to remnant tissue. In one case local recurrence, in ten cases lymph node metastases (one false-positive, caused by sarcoidosis) and in three cases distant metastases were found with FDG PET. In comparison with whole-body scintigraphy using iodine-131 (WBS) there were a lot of discrepancies in imaging results. Whereas three patients had distant metastases (proven with {sup 131}I) and a negative FDG PET, in four cases {sup 131}I-negative lymph node metastases were detectable with PET. Even in the patients with concordant ``staging``, differences between {sup 131}I and FDG were observed as to the exact lesion localization. Therefore, a coexistence of {sup 131}I-positive/FDG-negative, {sup 131}I-negative/FDG-positive and {sup 131}I-positive/FDG-positive malignant tissue can be assumed in these patients. A higher correlation of FDG  More>>
Authors:
Gruenwald, F; [1]  Schomburg, A; [1]  Bender, H; [1]  Klemm, E; [1]  Menzel, C; [1]  Bultmann, T; [1]  Palmedo, H; [1]  Ruhlmann, J; [1]  Kozak, B; [1]  Biersack, H J [1] 
  1. Department of Nuclear Medicine, University of Bonn, Sigmund-Freud-Strasse 25, D-53127 Bonn (Germany)
Publication Date:
Mar 01, 1996
Product Type:
Journal Article
Reference Number:
SCA: 550601; PA: DEN-96:0F6542; EDB-96:068264; SN: 96001571644
Resource Relation:
Journal Name: European Journal of Nuclear Medicine; Journal Volume: 23; Journal Issue: 3; Other Information: PBD: Mar 1996
Subject:
55 BIOLOGY AND MEDICINE, BASIC STUDIES; THYROID; POSITRON COMPUTED TOMOGRAPHY; CARCINOMAS; DIAGNOSIS; FLUORINE 18; FLUORODEOXYGLUCOSE; PATIENTS; RADIOPHARMACEUTICALS; SCINTISCANNING; IODINE 131; LYMPH NODES; METASTASES; TECHNETIUM 99; TECHNETIUM COMPLEXES; ISONITRILES; COMPARATIVE EVALUATIONS; ACCURACY
OSTI ID:
209782
Country of Origin:
Germany
Language:
English
Other Identifying Numbers:
Journal ID: EJNMD9; ISSN 0340-6997; TRN: DE96F6542
Submitting Site:
DEN
Size:
pp. 312-319
Announcement Date:
Apr 24, 1996

Journal Article:

Citation Formats

Gruenwald, F, Schomburg, A, Bender, H, Klemm, E, Menzel, C, Bultmann, T, Palmedo, H, Ruhlmann, J, Kozak, B, and Biersack, H J. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Germany: N. p., 1996. Web. doi:10.1007/BF00837630.
Gruenwald, F, Schomburg, A, Bender, H, Klemm, E, Menzel, C, Bultmann, T, Palmedo, H, Ruhlmann, J, Kozak, B, & Biersack, H J. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Germany. doi:10.1007/BF00837630.
Gruenwald, F, Schomburg, A, Bender, H, Klemm, E, Menzel, C, Bultmann, T, Palmedo, H, Ruhlmann, J, Kozak, B, and Biersack, H J. 1996. "Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer." Germany. doi:10.1007/BF00837630. https://www.osti.gov/servlets/purl/10.1007/BF00837630.
@misc{etde_209782,
title = {Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer}
author = {Gruenwald, F, Schomburg, A, Bender, H, Klemm, E, Menzel, C, Bultmann, T, Palmedo, H, Ruhlmann, J, Kozak, B, and Biersack, H J}
abstractNote = {Whole-body fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging was performed during the follow-up of 33 patients suffering from differentiated thyroid cancer. Among them there were 26 patients with papillary and seven with follicular tumours. Primary tumour stage (pT) was pT1 in six cases, pT2 in eight cases, pT3 in three cases and pT4 in 14 cases. FDG PET was normal in 18 patients. In three patients a slightly increased metabolism was observed in the thyroid bed, assumed to be related to remnant tissue. In one case local recurrence, in ten cases lymph node metastases (one false-positive, caused by sarcoidosis) and in three cases distant metastases were found with FDG PET. In comparison with whole-body scintigraphy using iodine-131 (WBS) there were a lot of discrepancies in imaging results. Whereas three patients had distant metastases (proven with {sup 131}I) and a negative FDG PET, in four cases {sup 131}I-negative lymph node metastases were detectable with PET. Even in the patients with concordant ``staging``, differences between {sup 131}I and FDG were observed as to the exact lesion localization. Therefore, a coexistence of {sup 131}I-positive/FDG-negative, {sup 131}I-negative/FDG-positive and {sup 131}I-positive/FDG-positive malignant tissue can be assumed in these patients. A higher correlation of FDG PET was observed with hexakis (2-methoxyisobutylisonitrile) technetium-99m (I) (MIBI) scintigraphy (performed in 20 cases) than with WBS. In highly differentiated tumours {sup 131}I scintigraphy had a high sensitivity, whereas in poorly differentiated carcinomas FDG PET was superior. The clinical use of FDG PET can be recommended in all cases of suspected or proven recurrence and/or metastases of differentiated thyroid cancer and is particularly useful in cases with elevated serum thyroglobulin levels and negative WBS. (orig.). With 3 figs., 2 tabs.}
doi = {10.1007/BF00837630}
journal = {European Journal of Nuclear Medicine}
issue = {3}
volume = {23}
journal type = {AC}
place = {Germany}
year = {1996}
month = {Mar}
}